FINWIRES · TerminalLIVE
FINWIRES

$TFX

6 stories mentioning TFX

Every FINWIRES story that references TFX, newest first.

Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Tuesday

Healthcare stocks were rising pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) advancing by 1%.TG Therapeutics (TGTX) shares were up more than 3% after the company said it has started a phase 2 trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with myasthenia gravis, a chronic autoimmune neuromuscular disease.Teleflex (TFX) stock was up more than 1% after the company said four-year follow-up data from its BIOMAG-I study continued to show a favorable long-term safety profile for its Freesolve resorbable magnesium scaffold.Novanta (NOVT) shares were down more than 7% after the company signed a securities purchase agreement for the private placement of about 2.1 million common shares at $140 per share to institutional and other accredited investors, for total proceeds of approximately $300 million. Novanta also said it has agreed to acquire Riverpoint Medical from Arlington Capital Partners for a $1.2 billion upfront cash consideration and potential $250 million milestone payment in Q1.

$IBB$NOVT$TFX$TGTX$XLV
Research

Research Alert: CFRA Maintains Hold Rating On Tfx On Q1 Margin Compression

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target to $110 from $136, 12.5x our 2027 EPS view. We cut our 2026 EPS view to $6.46 from $6.54. We keep our 2027 EPS view at $8.82. We reaffirmed our fundamental outlook for the health care equipment sub-industry for the next 12 months as neutral. While we anticipate continued growth in elective procedures and diagnostics, we see tariffs and rising costs as considerable pressure points on profitability, especially for smaller firms in our coverage. TFX faced severe margin compression in Q1, with adj. gross margin and operating margin declining by 470 bps and 510 bps, respectively. This pressure, led by tariffs, higher logistics costs, the dilutive impact of the Vascular acquisition, and a quality remediation charge for a recall, led to a 3.5% Y/Y decrease in EPS. Compounding these challenges, the key Interventional segment (37% of total) posted modest 3% growth due to disruption from its sales force integration, and we are concerned the supplier recall may lead to elevated backorders in Q2.

$TFX
Research

Research Alert: CFRA Keeps Hold Rating On Shares Of Teleflex Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target to $136 from $128, 15.4x our 2027 EPS forecast. We raise our 2026 EPS estimate to $6.54 from $6.50 and retain our 2027 EPS estimate at $8.82. Teleflex reported a solid start to 2026, with first-quarter results surpassing consensus estimates for both revenue and EPS. This performance comes amid a significant corporate transformation, as Teleflex progresses with the strategic divestitures of its acute care, interventional urology, and OEM businesses. The planned sale of the acute care and interventional urology businesses received a second request for information from the U.S. FTC, indicating a more in-depth antitrust review. While TFX still expects a closing in 2H 2026, this adds a layer of uncertainty and may create a potential delay, in our view. The company announced the appointment of Jason Weidman as its new President and CEO, effective June 8, who brings 25+ years of industry experience and clears a key leadership uncertainty during this transformational period.

$TFX
Research

RBC Upgrades Teleflex to Outperform From Sector Perform, Raises Price Target to $155 From $135

Teleflex (TFX) has an average rating of hold and mean price target of $142.78, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TFX
Research

Research Alert: Teleflex Q1 Beats Expectations, Advances Portfolio Transformation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Teleflex delivered Q1 2026 results with revenue of $548.3M (+32.3% Y/Y), $11M above the consensus, though pro forma adjusted constant currency growth of 5.1% reflects underlying momentum. Adjusted EPS of $1.39 met the consensus but declined from $1.44 the prior year, with significant margin compression as adjusted gross margin fell 470 bps to 61.4% due to tariffs, quality charges, and BIOTRONIK integration. Portfolio transformation shows mixed segment results, with Surgical leading at 9.9% pro forma growth while Interventional faced integration challenges at 3.0% growth. Management maintained full-year 2026 adjusted EPS guidance of $6.25-$6.55, incorporating $90M in stranded costs from divestitures. The company announced a new CEO, Jason Weidman, effective June 8, bringing 25+ years medical device experience as the company focuses on its portfolio optimization plans. We expect the $90M stranded costs fully offset by transition services beginning 2027, providing clearer standalone financial visibility.

$TFX
Wire

Teleflex Names Jason Weidman as President, CEO

Teleflex (TFX) said Thursday it has appointed Jason Weidman as president and chief executive officer, starting June 8.Weidman will succeed interim CEO Stuart Randle, who will remain on the company's board of directors, it added.Shares of Teleflex were down nearly 6% in Thursday trading.Price: $125.69, Change: $-7.61, Percent Change: -5.71%

$TFX